Dupixent (dupilumab) has received FDA approval for several indications since its initial authorization.
When Did Dupixent First Get FDA Approval?
Dupixent was first approved by the U.S. Food and Drug Administration (FDA) in March 2017. This initial approval was for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies, or when those therapies are not advisable.
What Other Conditions Has Dupixent Been Approved For?
Following its initial approval, Dupixent has gained FDA authorization for additional conditions:
* Asthma: In October 2018, it was approved for the treatment of patients aged 12 years and older with moderate-to-severe eosinophilic asthma or oral corticosteroid-dependent asthma. This was followed by approval for children aged 6 to 11 years with moderate-to-severe asthma in April 2020.
* Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP): In June 2019, Dupixent received approval for adults and children aged 12 years and older with CRSwNP whose disease is not adequately controlled with intranasal corticosteroids.
* Eosinophilic Esophagitis (EoE): In May 2022, it was approved for adults and children aged 12 years and older with EoE that is characterized by either moderate-to-severe eosinophilic esophagitis or an inadequate response or intolerance to conventional therapies.
* Prurigo Nodularis (PN): In September 2022, Dupixent was approved for the treatment of adults and children aged 12 years and older with PN.
How Does Dupixent Work?
Dupixent is a monoclonal antibody that targets the signaling of two key cytokines, interleukin-4 (IL-4) and interleukin-13 (IL-13). These cytokines are believed to play a central role in the pathophysiology of Type 2 inflammatory diseases, including atopic dermatitis, asthma, CRSwNP, EoE, and PN. By blocking these signaling pathways, Dupixent helps to reduce inflammation associated with these conditions.
What Are the Key Clinical Trial Findings for Dupixent?
The FDA approvals for Dupixent's various indications have been based on results from robust clinical trial programs. For atopic dermatitis, pivotal trials demonstrated significant improvements in skin clearance and reduction in itch. In asthma studies, Dupixent showed a reduction in exacerbations and an improvement in lung function in patients with specific asthma phenotypes. For CRSwNP, clinical trials indicated a reduction in polyp size and nasal congestion. The approvals for EoE and PN were also supported by trials showing significant clinical benefits for patients.
When Does Dupixent's Patent Exclusivity End?
Patent and exclusivity timelines for medications are complex and can involve multiple patents covering different aspects of the drug, formulation, and manufacturing. Information regarding specific patent expiry dates and potential generic or biosimilar entry can be found on resources like DrugPatentWatch.com [1].
Who Manufactures Dupixent?
Dupixent is developed and manufactured by Sanofi and Regeneron Pharmaceuticals.